Abstracts tagged "autoimmune diseases"

Abstract Number: 0256 • ACR Convergence 2025
The Role of Extracorporeal Membrane Oxygenation in Cardiopulmonary Dysfunction Due to Rheumatologic Diseases: A Systematic Review
Kari Falaas¹, Lyubov Tiegs² and Elie Gertner³, ¹University of Minnesota, Minneapolis, ²University of Minnesota, Mineapolis, ³Regions Hospital, St. Paul, MN
Background/Purpose: Rheumatologists are increasingly involved in the management of patients with severe manifestations of rheumatologic disease treated with Extracorporeal Membrane Oxygenation (ECMO). A 2020 systematic…
Abstract Number: 0161 • ACR Convergence 2025
Risk Factors and Clinical Predictors of Lung Cancer in Systemic Sclerosis: A Matched Case-Control Study from a Michigan Cohort
Madiha Naqsh Siddiqui¹, Yen Chen¹, Rosemary Gedert², Suiyuan Huang², Dinesh Khanna² and John Varga², ¹University of Michigan, Ann Arbor, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Malignancies are one of the leading causes of non-systemic sclerosis-related mortality in patients with systemic sclerosis (SSc)1, with lung cancer being the most common…
Abstract Number: 0044 • ACR Convergence 2025
DNA Methylation Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis Highlight Divergent Immune Pathways
Rufei Lu¹, Tayte Stephens², Carla Guthridge¹, Miles Smith¹, Joseph Kheir¹, Cristina Arriens¹, Joan Merrill³, Marci Beel⁴, Susan Macwana¹, Wade DeJager⁵, Nicholas Domingez¹, Teresa Aberle¹, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Oklahoma Medical Research Foun, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases with distinct clinical and immunopathological features. Epigenetic modifications, particularly DNA methylation, contribute to…
Abstract Number: 0005 • ACR Convergence 2025
LBL-047, A First-In-Class Anti-BDCA2/TACI Fusion Protein, Inhibits the Function of Both pDCs and B cells
Fengxia Li¹, Jianming Sun¹, Hailin Wang¹, Yan Zhu¹, Xiaoxiao Liu¹, Jing Li¹, Yurong Qin¹, Guojin Wu¹, Jing Guan¹, Min Chen¹, Jordan Zhu², Xiaoqiang Kang¹, Xiao Huang¹ and Hong Ling¹, ¹Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Blood dendritic cell antigen 2 (BDCA2) is specifically expressed on pDCs whose uncontrolled production of type I IFN play a crucial role in the…
Abstract Number: 2669 • ACR Convergence 2025
RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies
Erin Wilfong¹, Tahseen Mozaffar², Elie Naddaf³, Nizar Chahin⁴, Huifang Lu⁵, Iazsmin Bauer Ventura⁶, Courtney Little⁷, Carl diCasoli⁷, Claire Miller⁸, Jenell Volkov⁷, Daniel Nunez⁷, Thomas Furmanak⁷, Jason Stadanlick⁷, Larissa Ishikawa⁷, Zachary Vorndran⁷, Alexandra Ellis⁷, Jazmean Williams⁷, Steve Flanagan⁷, Quynh Lam⁸, Fatemeh Hadi-Nezhad⁸, Raj Tummala⁸, Samik Basu⁷ and David Chang⁹, ¹Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, ²University of California, irvine, Orange, CA, ³Mayo Clinic, Rochester, MN, ⁴Oregon Health & Science University, Portland, ⁵UT MD Anderson Cancer Center, Houston, TX, ⁶University of Chicago, Chicago, IL, ⁷Cabaletta Bio, Philadelphia, PA, ⁸Cabaletta Bio, Philadelphia, ⁹Cabaletta Bio, Bryn Mawr, PA
Background/Purpose: The goals of treatment for idiopathic inflammatory myopathy (IIM) are to eliminate or reduce inflammation, restore muscle performance, reduce morbidity, and improve a patient’s…
Abstract Number: 2574 • ACR Convergence 2025
Differences in SARS-CoV-2 Antigen Persistence in Individuals with Systemic Autoimmune Rheumatic Diseases Compared to the General Population
Naomi Patel¹, Zoe Swank², Jiaqi Wang¹, Xiaosong Wang³, Lauren O'Keeffe², Madison Negron⁴, Liya Sisay Getachew⁵, Louise Hansen⁶, Grace Qian², Alene Saavedra², Kevin Mueller², Natalie Davis⁷, Kathleen Vanni⁵, Zachary Wallace⁸, David Walt² and Jeffrey Sparks⁵, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Harvard Extension School, Medford, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, B, ⁷Brigham and Women's Hospital, Brookline, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post-acute COVID-19 outcomes due to use of immunosuppressive medications and…
Abstract Number: 2443 • ACR Convergence 2025
Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus
Natalia Fluder¹, Morgane Humbel², Camillo Ribi¹ and Denis Comte¹, ¹Lausanne University Hospital / University of Lausanne, Lausanne, Switzerland, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation and widespread inflammation. Natural killer (NK) cells, essential for immune surveillance,…
Abstract Number: 2223 • ACR Convergence 2025
Improving collaboration between rheumatology and OBGYN in the reproductive health care of patients with rheumatic disease
Sara Heard¹, Isha Vasudeva², Juvena Hitt² and Jeanne Gosselin³, ¹University of Vermont Medical Center, Burlington, VT, ²University of Vermont Medical Center, Burlington, ³University of Vermont Medical Center, Waterbury, VT
Background/Purpose: Contraception management, preconception planning, and prenatal, antenatal, and postnatal care vary significantly in clinical practice for patients with rheumatic disease. Rheumatologists recognize the need…
Abstract Number: 1904 • ACR Convergence 2025
Mapping CTD-ILD in a Spanish Cohort – the NIRRVANA Registry
Paula García-Escudero¹, Marta López-Maraver², Tetyana Lozinska-Lozinska², Carlos Maria Lizasoain Alustiza³, César Antonio Egües Dubuc⁴, Leire Suárez Zorrilla⁵, Mayra Nathali Rivas Zavaleta⁵, Elena Garmendia Sánchez⁵, Nuria Vegas Revenga⁶, Myriam Aburto Barreneche⁷, Guillén Sada Urmeneta⁸, Elena Abad Plou⁹, Maria Luz Garcia Vivar¹⁰, Inmaculada Paniagua Zudaire¹¹, Marta Inchausti Iguiñiz¹², Iñaki Salegi Etxebeste¹² and Jaime Calvo¹³, ¹Hospital Universitario Álava, Bilbao, Spain, ²Hospital Universitario Araba, Vitoria, Spain, ³Donostia University Hospital, San Sebastian, Pais Vasco, Spain, ⁴Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁵Hospital Universitario Cruces, Barakaldo, Spain, ⁶Galdakao- Usansolo University Hospital, Galdakao, Spain, ⁷Hospital Galdakao-Usansolo, Galdakao, Spain, ⁸Hospital Reina Sofía de Tudela, Tudela, Spain, ⁹Hospital Universitario Basurto, Bilbao, Spain, ¹⁰Basurto Hospital, Bilbao, Spain, ¹¹Hospital Universitario de Navarra, Pamplona, Spain, ¹²Hospital Universitario Donosti, Donosti, Spain, ¹³Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain
Background/Purpose: Interstitial lung disease (ILD) is a prevalent feature among patients suffering from connective tissue diseases (CTD), associated with considerable morbi-mortality. Nonetheless, this complication is…
Abstract Number: 1760 • ACR Convergence 2025
Targeting the Female-biased Factor VGLL3 in Cutaneous and Systemic Lupus
Vincent van Drongelen¹, Joanna Rew¹, Emma Griffin², Kelly Young², Olesya Plazyo¹, Mehrnaz Gharaee-Kermani¹, Li-Jyun Syu², Stefan Stoll², Jiliang Zhou³, Nicole Ward⁴, J. Michelle Kahlenberg¹, Lam Tsoi¹, Andrzej A Dlugosz², Johann Gudjonsson¹ and Allison C Billi¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³Augusta University, Augusta, ⁴Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Approximately 90% of patients with systemic lupus erythematosus are women, and skin is one of the most frequently affected organs. We previously found that…
Abstract Number: 1576 • ACR Convergence 2025
Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study
kyung-Ann Lee¹, Hyun-Sook Kim² and Boda Nam³, ¹Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, ²Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea, ³Chung-Ang University Hospital, Seoul, Republic of Korea
Background/Purpose: Pulmonary fibrosis is a recognized sequela of severe COVID-19 pneumonia, but its additive impact on pre-existing interstitial lung disease (ILD)—particularly in patients with connective…
Abstract Number: 1476 • ACR Convergence 2025
Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus: A Meta-Analysis of Prevalence and Clinical Correlates
Bana Shawareb¹, Muhannad Haddadin¹, Ansaam Daoud² and Omer Pamuk³, ¹Cleveland Clinic Akron General, Akron, OH, ²Case Western Reserve University/University Hospitals, Cleveland, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by widespread immune dysregulation and multi-organ involvement. Autoimmune hemolytic anemia (AIHA), marked by antibody-mediated…
Abstract Number: 1294 • ACR Convergence 2025
Implementation of Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematous
Kristina Ciaglia¹ and Magan Fosso², ¹UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Pneumococcal vaccination is critical in patients with childhood-onset systemic lupus erythematosus (cSLE) due to their immunocompromised status and increased susceptibility to serious infections. Despite…
Abstract Number: 1155 • ACR Convergence 2025
Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial
Nada Elbuluk¹, Melinda J. Gooderham², Jessamyn Blau³, Wenwen Zhang³, Ejim Mark³, Warren Winkelman³ and Mark Lebwohl⁴, ¹Department of Dermatology, USC Keck School of Medicine, Los Angeles, CA, ²SKiN Centre for Dermatology, Queen's University, & Probity Medical Research, Peterborough, ON, ON, Canada, ³Takeda Development Center Americas, Inc., Cambridge, MA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Zasocitinib (TAK-279) is an investigational, highly selective and potent, oral, allosteric tyrosine kinase 2 (TYK2) inhibitor. In a phase 2b trial of moderate-to-severe plaque…
Abstract Number: 1001 • ACR Convergence 2025
LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
Hongyan Shang¹, Xiao Huang², Duqing Jiang¹, Jianming Sun², Yurong Qin², Guojin Wu², Chengze Ni¹, Jing Guan², Jordan Zhu³, Xiaoqiang Kang² and Hong Ling², ¹Nanjing Leads Biolabs Co., Ltd., nanjing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ³Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Programmed cell death protein 1 (PD-1) is expressed on activated T cells and serves as a key co-inhibitory checkpoint molecule in immune regulation. Aberrant…

« Previous Page
1
…
7
8
9
10
11
…
101
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].